Literature DB >> 7359315

Serum levels of butorphanol by radioimmunoassay.

K A Pittman, R D Smyth, R F Mayol.   

Abstract

A radioimmunassay was developed for the analysis of butorphanol in human serum. The procedure involves extraction of serum with hexane containing 2% isoamyl alcohol, followed by evaporative solvent removal and radioimmunoassay of the reconstituted residue. The antibody significantly cross-reacts with unidentified butorphanol metabolites but not with two known metabolites, hydroxybutorphanol and norbutorphanol. Extraction eliminated interference from the butorphanol metabolites normally present in serum. The antibody also cross-reacts with pentazocine and cyclazocine but not with morphine, hydromorphone, oxymorphine, codeine, methadone, and meperidine. Butorphanol tartrate was administered intravenously (2 mg) to normal male volunteers. Serum butorphanol levels declined biexponentially with an average terminal half-life of 2.7 hr. Enzymatic serum hydrolysis prior to extraction yielded additional butorphanol, indicating the presence of butorphanol conjugates. The specificity of the assay for butorphanol was confirmed by GLC--mass fragmentography.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7359315     DOI: 10.1002/jps.2600690211

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

Authors:  M W Lo; F H Lee; W L Schary; C C Whitney
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

3.  The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis.

Authors:  W C Shyu; K A Pittman; D S Robinson; R H Barbhaiya
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management.

Authors:  J C Gillis; P Benfield; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

5.  The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol.

Authors:  W C Shyu; E A Morgenthien; K A Pittman; R H Barbhaiya
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.